Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors
This study has been completed.
Sponsor:
Pharmacyclics
Information provided by:
Pharmacyclics
ClinicalTrials.gov Identifier:
NCT00080041
First received: March 22, 2004
Last updated: May 11, 2007
Last verified: May 2007
Tracking Information | |
---|---|
First Received Date ICMJE | March 22, 2004 |
Last Updated Date | May 11, 2007 |
Start Date ICMJE | |
Primary Completion Date | |
Current Primary Outcome Measures ICMJE |
Determine the Dose Limiting Toxicity at 3 weeks (1 cycle), and the Maximum Tolerated Dose at 24 weeks (6 cycles). |
Original Primary Outcome Measures ICMJE | Same as current |
Change History | Complete list of historical versions of study NCT00080041 on ClinicalTrials.gov Archive Site |
Current Secondary Outcome Measures ICMJE |
Frequency of tumor responses at weeks 6, 12 and 18. |
Original Secondary Outcome Measures ICMJE | Same as current |
Current Other Outcome Measures ICMJE | |
Original Other Outcome Measures ICMJE | |
Descriptive Information | |
Brief Title ICMJE | Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors |
Official Title ICMJE | Phase I Trial of Motexafin Gadolinium (MGd) and Docetaxel Administered at 3-Week Intervals for Advanced Solid Tumors |
Brief Summary | The primary purpose of this study is to evaluate the safety, toxicities, and dosage for investigational drug Motexafin Gadolinium administered with docetaxel to patients with advanced solid tumors. Secondly, tumor response to the combined treatment will be evaluated. |
Detailed Description | |
Study Type ICMJE | Interventional |
Study Phase | Phase 1 |
Study Design ICMJE | Allocation: Non-Randomized Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
Condition ICMJE |
|
Intervention ICMJE | Drug: Motexafin Gadolinium Injection |
Study Arm (s) | |
Publications * | |
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|
Recruitment Information | |
Recruitment Status ICMJE | Completed |
Enrollment ICMJE | 20 |
Completion Date | |
Primary Completion Date | |
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria: Laboratory Values of:
and
|
Gender | Both |
Ages | 18 Years and older |
Accepts Healthy Volunteers | No |
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects |
Location Countries ICMJE | United States |
Administrative Information | |
NCT Number ICMJE | NCT00080041 |
Other Study ID Numbers ICMJE | PCYC-0214 |
Has Data Monitoring Committee | |
Responsible Party | |
Study Sponsor ICMJE | Pharmacyclics |
Collaborators ICMJE | |
Investigators ICMJE | |
Information Provided By | Pharmacyclics |
Verification Date | May 2007 |
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |